Ascending Cholangitis

Ascending cholangitis is a life-threatening infection of the biliary tree resulting from the combination of biliary obstruction and bacterial growth in bile. It is most commonly caused by choledocholithiasis and can rapidly progress to sepsis and multiorgan failure if not promptly recognized and treated. [1-2] Mortality in severe cases historically ranges from 11–27%, and sepsis occurs in approximately 10–29% of patients. [2-3]

1. History

• Charcot triad: Fever/chills, jaundice, and RUQ abdominal pain — present in only ~50–70% of cases; sensitivity is limited [4-5]
• Reynolds pentad: Charcot triad + hypotension and altered mental status — indicates severe/suppurative cholangitis and is a late, ominous finding [4][6]
• Characterize pain: onset, location (RUQ/epigastric), radiation, severity, relationship to meals (especially fatty foods)
• Timing: acute onset over hours; ask about prior episodes of biliary colic or known gallstones
• Associated symptoms: nausea, vomiting, dark urine, clay-colored stools, pruritus
• Important negatives: diarrhea (suggests alternative GI source), hematuria, chest pain, dysuria
• Prior biliary interventions: ERCP, biliary stent placement, cholecystectomy, sphincterotomy — these are increasingly common causes [7-8]

2. Alarm Features

• Hemodynamic instability: hypotension, tachycardia → biliary sepsis/septic shock [9]
• Altered mental status → Reynolds pentad, severe cholangitis [4]
• Rigors with high-grade fever (>39°C)
• Signs of organ dysfunction: oliguria, respiratory distress, coagulopathy
• Failure to respond to initial antibiotics within 24–48 hours [9-10]
• Peritoneal signs suggesting perforation or concurrent pathology

3. Medications

Empiric Antibiotics (per TG18 and WSES): [11-12]

• Grade I (mild), community-acquired: Piperacillin-tazobactam, ceftriaxone + metronidazole, or fluoroquinolone + metronidazole
• Grade II–III (moderate-severe): Piperacillin-tazobactam or carbapenems (meropenem, imipenem) — especially if healthcare-associated, prior antibiotics, or biliary stent in situ [11][13]
• Add vancomycin or linezolid if Enterococcus is suspected (stent-associated, healthcare-associated) [14-15]
• Duration: 3–5 days after adequate biliary drainage for uncomplicated cases; longer for severe/healthcare-associated infections [12][16]

Medication contributors to consider: Anticoagulants (coagulopathy complicating drainage), immunosuppressants (increased infection risk)

Contraindicated: Avoid nephrotoxic agents (aminoglycosides) in cholestasis due to increased nephrotoxicity risk [17]

4. Diet

• NPO on presentation — anticipate need for ERCP or procedural intervention
• IV fluid resuscitation is the priority
• Once recovering: low-fat diet, advance as tolerated
• Long-term: low-fat, high-fiber diet to reduce gallstone recurrence if choledocholithiasis is the etiology
• Adequate hydration to prevent bile sludging

5. Review of Systems

• GI: Abdominal pain, nausea, vomiting, anorexia, stool color changes, prior biliary symptoms
• Constitutional: Fever, chills, rigors, night sweats, weight loss (malignancy screening)
• Skin: Jaundice, pruritus, bruising/bleeding (coagulopathy)
• Neurologic: Confusion, somnolence (Reynolds pentad)
• Cardiovascular: Palpitations, lightheadedness (sepsis)
• Urologic: Dark urine (bilirubinuria)

6. Collateral History and Family History

• Prior episodes of biliary colic, cholecystitis, pancreatitis, or cholangitis
• History of biliary interventions (ERCP, stent placement, cholecystectomy)
• Known gallstones or biliary strictures
• Recent hospitalizations or antibiotic use (risk for resistant organisms) [13]
• Family history of gallstone disease, biliary or pancreatic malignancy
• Social context: alcohol use (pancreatitis risk), travel history (parasitic causes such as Clonorchis/Ascaris in endemic areas)

7. Risk Factors

• Choledocholithiasis — most common cause (~53% of ICU admissions for severe cholangitis) [3][18]
• Malignant biliary obstruction — pancreatic head cancer, cholangiocarcinoma, ampullary tumors (~22% of severe cases) [3][19]
• Biliary stents — stent occlusion is a major risk factor; polymicrobial infections in 90% of stented patients [7][15]
• Prior ERCP with incomplete drainage [7]
• Benign biliary strictures (post-surgical, chronic pancreatitis, PSC)
• Parasitic infections (Clonorchis sinensis, Ascaris lumbricoides) — endemic areas
• Advancing age, male sex, liver disease, immunosuppression [20]
• Low serum albumin, malignant obstruction, and high Charlson Comorbidity Index are independent predictors of poor prognosis [21-22]

8. Differential Diagnosis

• Acute cholecystitis — Murphy sign positive, gallbladder wall thickening on US; typically no jaundice unless Mirizzi syndrome. Distinguished by the BILE criteria: cholangitis requires biliary imaging abnormalities, inflammatory markers, liver test abnormalities, and exclusion of cholecystitis/pancreatitis [23]
• Choledocholithiasis without cholangitis — elevated LFTs and CBD dilation but no fever/systemic inflammation
• Gallstone pancreatitis — epigastric pain radiating to back, elevated lipase >3× ULN
• Hepatic abscess — fever, RUQ pain, may have similar labs; CT shows focal hepatic lesion
• Acute hepatitis (viral, alcoholic, drug-induced) — transaminases markedly elevated, no biliary dilation
• Perforated peptic ulcer — sudden onset, peritoneal signs, free air on imaging
• Right lower lobe pneumonia — can mimic RUQ pain; CXR diagnostic
• Acute mesenteric ischemia — pain out of proportion to exam, lactate elevation
• Fitz-Hugh-Curtis syndrome — RUQ pain with perihepatitis, typically in young women

9. Past Medical History

• Prior gallstone disease, cholecystectomy, biliary surgery
• Previous episodes of cholangitis (recurrence is common, especially with stents or strictures) [24]
• Known biliary or pancreatic malignancy
• Chronic liver disease, cirrhosis
• Diabetes mellitus (increased infection risk)
• Immunosuppression (transplant, chemotherapy, HIV)
• Inflammatory bowel disease (association with PSC)

10. Physical Exam

Vital signs

Focused exam

• Jaundice — scleral icterus, skin
• RUQ tenderness — may be diffuse; peritoneal signs are uncommon unless perforation
• Murphy sign — more specific for cholecystitis; may be positive if concurrent cholecystitis
• Hepatomegaly — may be present with biliary obstruction
• Altered mental status — confusion, obtundation (Reynolds pentad) [4]
• Skin excoriations from pruritus
• Signs of chronic liver disease (spider angiomata, palmar erythema, ascites) if underlying hepatic pathology

11. Lab Studies

Recommended initial labs

• CBC: Leukocytosis (or leukopenia in severe sepsis)
• CMP: Elevated total bilirubin (often >2 mg/dL), elevated ALP and GGT (cholestatic pattern), transaminases may be mildly elevated
• Lipase: To rule out concurrent pancreatitis
• Coagulation studies: PT/INR — may be prolonged due to cholestasis-related vitamin K malabsorption or DIC
• Lactate: Elevated in sepsis/shock
• Blood cultures (×2 sets before antibiotics): Positive in ~21–46% of cases [15][25]
• Procalcitonin: Best biomarker for differentiating mild from severe cholangitis (AUC 0.80) [25]
• CRP: Useful for differentiating mild from moderate disease [25]

Expected abnormalities: Conjugated hyperbilirubinemia, elevated ALP/GGT >> AST/ALT, leukocytosis, elevated inflammatory markers [3][26]

12. Imaging

First-line: Right upper quadrant ultrasound — recommended initial imaging modality per IDSA 2024 guidelines [26]

• Findings: CBD dilation (>6 mm, or >8 mm post-cholecystectomy), choledocholithiasis, intrahepatic ductal dilation
• Sensitivity for CBD stones is limited (~50%), but dilation is suggestive

Second-line: CT abdomen/pelvis with IV contrast — if US is equivocal or to evaluate for alternative diagnoses, malignancy, or complications [26]

Gold standard for biliary anatomy: MRCP — if US and CT are inconclusive and clinical suspicion persists; excellent for detecting CBD stones and strictures without procedural risk [26-27]

When imaging is unnecessary: Imaging should not delay resuscitation or antibiotics in a clinically obvious presentation. ERCP is both diagnostic and therapeutic and should not be delayed for additional imaging in clear-cut cases [9]

13. Special Tests

Diagnostic scoring systems

• Tokyo Guidelines 2018 (TG18) — the international standard for diagnosis and severity grading: [28]
  • Suspected diagnosis: Systemic inflammation (fever, elevated WBC/CRP) + cholestasis (jaundice, abnormal LFTs) OR biliary imaging abnormality
  • Definite diagnosis: All three domains present
  • Severity grading:
    • Grade I (mild): Does not meet criteria for Grade II or III
    • Grade II (moderate): Any 2 of: WBC >12,000 or <4,000, fever ≥39°C, age ≥75, bilirubin ≥5 mg/dL, albumin <0.7× lower limit of normal
    • Grade III (severe): Organ dysfunction (cardiovascular, neurologic, respiratory, renal, hepatic, hematologic)
• Charcot triad: High specificity (~97–99%) but low sensitivity (~25–47%) [5][29]
• BILE criteria (proposed): Biliary imaging abnormalities, Inflammatory test abnormalities, Liver test abnormalities, Exclusion of cholecystitis/pancreatitis [23]

Point-of-care tests: Bedside US for CBD dilation, POCUS for free fluid

Procedures: ERCP with bile culture at time of drainage — bile cultures positive in 55–98% of cases depending on stent status [15]

14. ECG

• ECG is not a primary diagnostic tool for cholangitis but should be obtained in:
  • Patients with hemodynamic instability or sepsis
  • Elderly patients or those with cardiac history to rule out ACS as a mimic or complication
• Biliary-cardiac reflex: Acute biliary disease can cause nonspecific ST-T wave changes, arrhythmias, or angina via a vagally mediated cardio-biliary reflex [30]
• Sepsis-related ECG findings: Sinus tachycardia (most common), atrial fibrillation/flutter (8.8% of sepsis patients), QT prolongation (54.4%), and new-onset AF — all associated with worse outcomes [31]

15. Assessment

Clinical summary: Ascending cholangitis is a clinical diagnosis supported by the triad of fever, jaundice, and RUQ pain in the setting of biliary obstruction. The TG18 criteria provide the most validated diagnostic framework. [28] Severity ranges from mild (responsive to antibiotics alone) to severe (organ dysfunction requiring ICU care and emergent drainage).

Severity stratification (per TG18): [9][28]

• Mild (Grade I): Responds to initial medical therapy; biliary drainage may not be needed
• Moderate (Grade II): Requires early biliary drainage (within 24–48 hours)
• Severe (Grade III): Organ dysfunction; requires ICU-level care and urgent biliary drainage after hemodynamic stabilization

Complications: Sepsis/septic shock (10–29%), hepatic abscess, portal vein thrombosis, multiorgan failure, DIC, acute kidney injury [3]

16. Treatment Plan

Initial stabilization (ED)

• ABCs, IV access (large-bore ×2), continuous monitoring
• Aggressive IV fluid resuscitation — crystalloid bolus for sepsis/hypotension
• Empiric IV antibiotics — start immediately after blood cultures are drawn: [9][11]
  • Community-acquired, mild-moderate: Piperacillin-tazobactam 4.5 g IV q6h or ceftriaxone 2 g IV + metronidazole 500 mg IV
  • Severe/healthcare-associated/stent-related: Meropenem 1 g IV q8h or imipenem 500 mg IV q6h ± vancomycin [11][13]
• Analgesics: Acetaminophen, opioids as needed; NSAIDs with caution
• Vasopressors if refractory hypotension after fluid resuscitation

Biliary drainage: [32-34]

• ERCP is the treatment of choice for biliary decompression
  • Timing: Within 24 hours for moderate-severe cholangitis (mortality benefit: 0.5% vs 21% in one propensity-matched study); within 48 hours per ASGE guidelines [33-34]
  • Biliary drainage combined with sphincterotomy and stone removal is preferred over stent placement alone when feasible [33]
• Percutaneous transhepatic biliary drainage (PTBD): Alternative when ERCP fails or is not feasible (e.g., surgically altered anatomy) [33][35]
• EUS-guided biliary drainage: Emerging alternative for failed ERCP [2][36]
• Open surgical drainage: Last resort; associated with highest morbidity/mortality [35]

Antibiotic duration: 3–5 days after adequate source control for uncomplicated cases; longer courses for inadequate drainage, abscess, or healthcare-associated infections [12]

17. Disposition

Admission criteria — virtually all patients with ascending cholangitis require admission:

• ICU admission: Grade III (severe) cholangitis with organ dysfunction, septic shock, need for vasopressors, or altered mental status [9][37]
• Floor/step-down: Grade I–II cholangitis responding to initial resuscitation

Observation: Not appropriate — cholangitis requires inpatient management with monitoring for clinical deterioration

Specialist consultation triggers

• GI/ERCP: All cases — early consultation for biliary drainage planning
• Interventional radiology: If ERCP fails or is not feasible (PTBD)
• Surgery: If endoscopic and percutaneous approaches fail; concurrent cholecystitis requiring cholecystectomy
• Critical care: Grade III cholangitis, septic shock, multiorgan failure

18. Follow Up / Return Precautions

Follow-up timing

• GI follow-up within 1–2 weeks post-discharge for repeat labs and assessment
• If biliary stent placed: scheduled stent exchange at ~3-month intervals for plastic stents, or at first sign of occlusion [7]
• Cholecystectomy should be planned during the same admission or within 2–4 weeks if choledocholithiasis was the etiology [18]

Return precautions — instruct patients to return immediately for:

• Recurrent fever, chills, or rigors
• Worsening abdominal pain or jaundice
• Dark urine or clay-colored stools
• Nausea/vomiting preventing oral intake
• Confusion or lightheadedness

Patient counseling

• Explain the risk of recurrence, especially with retained stones or biliary stents [19][24]
• Emphasize importance of completing antibiotic course and attending follow-up
• Discuss cholecystectomy planning if applicable

Expected recovery: Most patients with mild-moderate cholangitis improve within 24–48 hours of antibiotics and drainage. Median hospital stay is 5–9 days depending on severity and timing of ERCP. [34][38] Approximately 95% of patients survive an episode of cholangitis when the underlying cause is benign. [8]

References

1. Acute Cholangitis: Causes, Diagnosis, and Management. — An Z, Braseth AL, Sahar N. Gastroenterology Clinics of North America. 2021.

2. Acute Cholangitis: Current Concepts. — Lan Cheong Wah D, Christophi C, Muralidharan V. ANZ Journal of Surgery. 2017.

3. Machine-Learning-Derived Online Prediction Models of Outcomes for Patients With Cholelithiasis-Induced Acute Cholangitis: Development and Validation in Two Retrospective Cohorts. — Huang S, Zhou Y, Liang Y, et al. EClinicalMedicine. 2024.

4. Diagnosis and Management of Acute Cholangitis. — Lee JG. Nature Reviews. Gastroenterology & Hepatology. 2009.

5. Validation of Charcot's Triad and Tokyo Guidelines 2018 as a Diagnostic Tool for Acute Ascending Cholangitis Secondary to a Liver Cystic Echinococcosis. — Chaouch MA, Dougaz MW, Bergaoui MM, et al. BMC Infectious Diseases. 2025.

6. Acute (Ascending) Cholangitis. — Hanau LH, Steigbigel NH. Infectious Disease Clinics of North America. 2000.

7. Adverse Events Associated With ERCP. — Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Gastrointestinal Endoscopy. 2017.

8. Acute Cholangitis. — Lipsett PA, Pitt HA. The Surgical Clinics of North America. 1990.

9. Tokyo Guidelines 2018: Initial Management of Acute Biliary Infection and Flowchart for Acute Cholangitis. — Miura F, Okamoto K, Takada T, et al. Journal of Hepato-Biliary-Pancreatic Sciences. 2018.

10. 2013 WSES Guidelines for Management of Intra-Abdominal Infections. — Sartelli M, Viale P, Catena F, et al. World Journal of Emergency Surgery : WJES. 2013.

11. Tokyo Guidelines 2018: Antimicrobial Therapy for Acute Cholangitis and Cholecystitis. — Gomi H, Solomkin JS, Schlossberg D, et al. Journal of Hepato-Biliary-Pancreatic Sciences. 2018.

12. Source Control in Emergency General Surgery: WSES, GAIS, SIS-E, SIS-A Guidelines. — Coccolini F, Sartelli M, Sawyer R, et al. World Journal of Emergency Surgery : WJES. 2023.

13. Use of Microbiological and Patient Data for Choice of Empirical Antibiotic Therapy in Acute Cholangitis. — Kruis T, Güse-Jaschuck S, Siegmund B, Adam T, Epple HJ. BMC Gastroenterology. 2020.

14. Epidemiological, Clinical and Microbiological Characteristics of Patients With Biliary Tract Diseases With Positive Bile Culture in a Tertiary Hospital. — Liu T, Li M, Tang L, et al. BMC Infectious Diseases. 2024.

15. Microbiology of Bile in Patients With Cholangitis or Cholestasis With and Without Plastic Biliary Endoprosthesis. — Rerknimitr R, Fogel EL, Kalayci C, et al. Gastrointestinal Endoscopy. 2002.

16. Antibiotic Treatment for 1 day Versus 4-7 days in Patients With Acute Cholangitis After Adequate Endoscopic Biliary Drainage (COBRA): Study Protocol for a Randomized Controlled Trial. — Overdevest AG, Sieswerda E, Haal S, et al. Trials. 2026.

17. Biliary Tract Infections: A Guide to Drug Treatment. — Westphal JF, Brogard JM. Drugs. 1999.

18. Gallstone Disease: Common Questions and Answers. — Patel H, Jepsen J. American Family Physician. 2024.

19. Risk Factors for the Development of Stent-Associated Cholangitis Following Endoscopic Biliary Stent Placement. — Everett BT, Naud S, Zubarik RS. Digestive Diseases and Sciences. 2019.

20. Epidemiology of Biliary Tract-Associated Bloodstream Infections and Adequacy of Empiric Therapy: An Australian Population-Based Study. — Gassiep I, Edwards F, Laupland KB. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2024.

21. Clinical Applicability of Tokyo Guidelines 2018/­2013 in Diagnosis and Severity Evaluation of Acute Cholangitis and Determination of a New Severity Model. — Gravito-Soares E, Gravito-Soares M, Gomes D, Almeida N, Tomé L. Scandinavian Journal of Gastroenterology. 2018.

22. Predictive Risk Factors Associated With Cholangitis Following ERCP. — Tierney J, Bhutiani N, Stamp B, et al. Surgical Endoscopy. 2018.

23. Toward an Evidence-Based Approach for Cholangitis Diagnosis. — Buxbaum J, Qumseya B, Wani S. Gastrointestinal Endoscopy. 2021.

24. Duration and Predictive Factors of Plastic Biliary Stent Patency: Results of a Large Prospective Database Analysis. — Dieninyte E, Jasiunas E, Lemezis A, et al. Journal of Clinical Medicine. 2025.

25. The Predictive Value of Different Laboratory Indicators Based on the 2018 Tokyo Guidelines for the Severity of Acute Cholangitis. — Ye S, Lyu Y, Wang B. The Journal of Emergency Medicine. 2023.

26. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Complicated Intra-Abdominal Infections: Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation in Adults, Children, and Pregnant People. — Bonomo RA, Chow AW, Edwards MS, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

27. Acute Cholecystitis and Acute Cholangitis: The Radiologist's Role in Diagnosis and Management. — Martínez Márquez RJ, Cienfuegos Alvear JA, Torres Monarrez AA, Alpízar Cruz RD. Abdominal Radiology. 2026.

28. Tokyo Guidelines 2018: Diagnostic Criteria and Severity Grading of Acute Cholangitis (With Videos). — Kiriyama S, Kozaka K, Takada T, et al. Journal of Hepato-Biliary-Pancreatic Sciences. 2018.

29. Performance of Diagnostic Tools for Acute Cholangitis in Patients With Suspected Biliary Obstruction. — Sperna Weiland CJ, Busch CBE, Bhalla A, et al. Journal of Hepato-Biliary-Pancreatic Sciences. 2022.

30. Electrocardiographic Changes in Cardiac Patients With Acute Gallbladder Disease. — Krasna MJ, Flancbaum L. The American Surgeon. 1986.

31. Association of Electrocardiogram Abnormalities With Clinical Outcomes in Emergency Department Sepsis Patients. — Kotruchin P, Chuehongthong M, Tangpaisarn T, et al. The Western Journal of Emergency Medicine. 2026.

32. Emergent Versus Urgent ERCP in Acute Cholangitis: A Systematic Review and Meta-Analysis. — Iqbal U, Khara HS, Hu Y, et al. Gastrointestinal Endoscopy. 2020.

33. ASGE Guideline on the Management of Cholangitis. — Buxbaum JL, Buitrago C, Lee A, et al. Gastrointestinal Endoscopy. 2021.

34. Urgent Endoscopic Retrograde Cholangiopancreatography Improves Clinical Outcomes in Acute Cholangitis From Choledocholithiasis: A Propensity Score-Matched Study. — Kongsakon R, Rugivarodom M, Phisalprapa P, et al. Surgical Endoscopy. 2025.

35. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. — Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. World Journal of Emergency Surgery : WJES. 2017.

36. Early Management of Severe Biliary Infection in the Era of the Tokyo Guidelines. — Nve E, Badia JM, Amillo-Zaragüeta M, et al. Journal of Clinical Medicine. 2023.

37. Optimal Timing of Biliary Drainage Based on the Severity of Acute Cholangitis: A Single-Center Retrospective Cohort Study. — Lu ZQ, Zhang HY, Su CF, et al. World Journal of Gastroenterology. 2022.

38. Urgent One-Stage Endoscopic Treatment for Choledocholithiasis Related Moderate to Severe Acute Cholangitis: A Propensity Score-Matched Analysis. — Zhou Y, Zhang YQ, Huang SJ, et al. World Journal of Gastroenterology. 2024.